Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.60 |
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 2/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433264 | 1.00 | XDH (0.61) | XDHCA12CA1CA2CA7 | |
| SCHEMBL2797668 | 0.94 | TPMT (0.58) | XDHCA12CA1CA2CA7 | |
| SCHEMBL2797670 | 0.90 | MAPT (0.51) | XDHCA12CA1CA2CA7 | |
| SCHEMBL531728 | 0.87 | VCAM1 (0.64) | XDHCA12CA1CA2CA7 | |
| SCHEMBL5734347 | 0.86 | VCAM1 (0.68) | VCAM1ERN1HPGDALDH1A1NPSR1 | |
| SCHEMBL1890677 | 0.83 | TSHR (0.68) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL4753199 | 0.83 | VCAM1 (0.60) | VCAM1ERN1HPGDALDH1A1NPSR1 | |
| SCHEMBL25484994 | 0.83 | GPR35 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL460048 | 0.83 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL310574 | 0.82 | VCAM1 (0.58) | VCAM1HPGDALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664845-A | Preparation method of Plk (Polo-like kinase) inhibitor drug intermediate 7-amino-2,3-dihydrobenzofuran-4-formic acid | HUNAN OUYA BIOLOG CO LTD | 2014-03-26 | — | — | CN | claimed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-3848370-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| CN-119735519-A | Method for improving clarity and color of solution in oxybuprocaine hydrochloride | 辰欣药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | UNIVERZA V LJUBLJANI (SI) | 2025-03-25 | — | — | US | disclosed |
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-13 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20250002455-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | UNIV LJUBLJANI (SI) | 2025-01-02 | — | — | US | disclosed |
| CN-1061413-A | Medicinal compound | LILLY INDUSTRIES LTD (GB) | 1992-05-27 | — | — | CN | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| US-5059621-A | Treatment of dermatologic ailments linked to keratinization disorder | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1991-10-22 | — | — | US | disclosed |
| US-4920140-A | Skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1990-04-24 | — | — | US | disclosed |
| US-4740519-A | Benzo (b) thiophene carboxylate derivatives and pharmaceutical compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1988-04-26 | — | — | US | disclosed |
| EP-0018731-B1 | MACROMOLECULAR GLYCOSIDASE SUBSTRATES | SYVA COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
| US-4281061-A | DETECTABLE SIGNAL FROM FLUORESCENT DYE OR LABELED ENZYME | SYVA COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4268663-A | COMPRISING A POLYSACCHARIDE SUPPORT, AN AMINE-CONTAINING SPACER ARM, AND A CHROMOGEN ENZYMATICALLY LABILE-LINKED TO A MONOSACCHARIDE; IMMUNOASSAY | SYVA COMPANY (US) | 1981-05-19 | — | — | US | disclosed |
| WO-1981000261-A1 | CHARGE EFFECTS IN IMMUNOASSAYS | SYVA CO (US) | 1981-02-05 | — | — | WO | disclosed |
| EP-0018731-A1 | Macromolecular glycosidase substrates | SYVA COMPANY (US) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002455-A1 | NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY | TOP1, TOP2A, TOP2B | XDH 394/4885CA12 4030/4885CA1 3352/4885 |
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | XDH 471/4885CA12 2443/4885CA1 1410/4885 |
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | XDH 2933/4885CA12 4112/4885CA1 2894/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | XDH 392/4885CA12 3756/4885CA1 3577/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | XDH 3822/4885CA12 4605/4885CA1 4096/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | XDH 392/4885CA12 3756/4885CA1 3577/4885 |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | TOP1, TOP2A, TOP2B | XDH 470/4885CA12 2788/4885CA1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.